Biomarkers and the design of clinical trials in cancer, Biomarkers in Medicine, vol.94, issue.3, pp.387-97, 2007. ,
DOI : 10.1093/jnci/93.14.1054
Biomarkers in clinical drug development: realizing the promise, Biomarkers in Medicine, vol.3, issue.6, pp.667-69, 2009. ,
DOI : 10.2217/bmm.09.61
Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials, Controlled Clinical Trials, vol.22, issue.5, pp.485-502, 2001. ,
DOI : 10.1016/S0197-2456(01)00153-2
Table of Pharmacogenomic Biomarkers in Drug Labels [en ligne Disponible sur, 2011. ,
Clinical application of pharmacogenetics, Trends in Molecular Medicine, vol.7, issue.5, pp.201-205, 2001. ,
DOI : 10.1016/S1471-4914(01)01986-4
Imaging biomarkers as surrogate endpoints for drug developement, European Journal of Nuclear Medicine and Molecular Imaging, vol.33, issue.16, pp.6-10, 2006. ,
Le biomarqueur comme outil de diagnostic compagnon de produits thérapeutiques, Impacts sur la R&D et sur les modèles économiques des industriels de la santé ,
Promises of Biomarkers in Drug Development ? A Reality Check, Chemical Biology & Drug Design, vol.11, issue.6, pp.381-94, 2007. ,
DOI : 10.1007/BF03256453
On target? The challenge of integrating biomarker research in drug development, Biomarkers in Medicine, vol.1, issue.1, pp.17-21, 2007. ,
DOI : 10.2217/17520363.1.1.17
Conference presentation at the Gastrointestinal Cancers Symposium, 2009. ,
Vectibix® Summary of Product Characteristics, Disponible sur, 2010. ,
Erbitux® Summary of Product Characteristics [en ligne] Disponible sur: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000558/human_ med_000769.jsp&murl=menus/medicines/medicines, pp.0-01, 2010. ,
Vectibix® Product Information [en ligne] Disponible sur: http://www.accessdata.fda.gov, 2009. ,
Erbitux® Product Information [en ligne] Disponible sur: http://www.accessdata.fda.gov, 2009. ,
Clinical implications of pharmacogenomics of statin treatment, The Pharmacogenomics Journal, vol.165, issue.4 Suppl, pp.360-74, 2006. ,
DOI : 10.1016/S0021-9150(02)00196-X
Haplotypes on Transcriptional Regulation and Warfarin Dose, New England Journal of Medicine, vol.352, issue.22, pp.2285-93, 2005. ,
DOI : 10.1056/NEJMoa044503
??1-Adrenergic receptor polymorphisms and left ventricular remodeling changes in response to ??-blocker therapy, Pharmacogenetics and Genomics, vol.15, issue.4, pp.227-261, 2005. ,
DOI : 10.1097/01213011-200504000-00006
The Path to Personalized Medicine, N Engl J Med, vol.363, issue.4, pp.434-442, 2010. ,
THE RENAL EXCRETION OF CREATININE IN MAN, Journal of Clinical Investigation, vol.14, issue.4, pp.403-413, 1935. ,
DOI : 10.1172/JCI100691
A Creatinin Tolerance Test for Renal Function, Acta Paediatrica, vol.17, issue.6, pp.535-544, 1953. ,
DOI : 10.1042/bj0200447
Creatinine Excretion in Renal Failure., Experimental Biology and Medicine, vol.85, issue.3, pp.446-454, 1954. ,
DOI : 10.3181/00379727-85-20912
Prediction of Creatinine Clearance from Serum Creatinine, Nephron, vol.16, issue.1, pp.31-41, 1976. ,
DOI : 10.1159/000180580
Effects of urea loading in patients with far-advanced renal failure, Mayo Clin Proc, vol.47, issue.1, pp.21-30, 1972. ,
Prognosis in Acute Organ-System Failure, Annals of Surgery, vol.202, issue.6, pp.685-93, 1985. ,
DOI : 10.1097/00000658-198512000-00004
How to improve estimation of renal function in the elderly, Rev Prat, vol.55, issue.20, pp.2223-2232, 2005. ,
Limitations of creatinine as a filtration marker in glomerulopathic patients, Kidney International, vol.28, issue.5, pp.830-838, 1985. ,
DOI : 10.1038/ki.1985.205
Qualification process for drug development tools [en ligne]. 2010 Disponible sur: http://www.fda.gov/downloads, 2011. ,
Qualification of novel technologies for drug development : guidance to applicants, Disponible sur, 0200. ,
Guidance for industry: Pharmacogenomic data submission [en ligne]. Mars Disponible sur: http://www.fda.gov, 2005. ,
Food and Drug Administration General principles Processing Joint FDA EMEA Voluntary Genomic Data Submissions (VGDSs) within the framework of the confidentiality arrangement, Disponible sur, 2009. ,
Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium, Nature Biotechnology, vol.28, issue.5, pp.455-62, 2010. ,
DOI : 10.1038/nbt0510-436
The Predictive Safety Testing Consortium: A synthesis of the goals, challenges and accomplishments of the Critical Path, Drug Discovery Today: Technologies, vol.4, issue.2, pp.47-50, 2007. ,
DOI : 10.1016/j.ddtec.2007.10.010
Final conclusions on the pilot joint EMEA/FDA VXDS experience on qualification of nephrotoxicity biomarkers, Disponible sur, 0200. ,
Reflection paper on co-development of pharmacogenomic biomarkers and assays in the context of drug development. Draft. [en ligne, 2010. ,
Biomarker method validation in anticancer drug development, British Journal of Pharmacology, vol.26, issue.Suppl 1, pp.646-56, 2008. ,
DOI : 10.1155/2002/929274
Fit-for-purpose biomarker method validation in anticancer drug development, Drug Discovery Today, vol.15, issue.19-20, pp.19-20, 2010. ,
DOI : 10.1016/j.drudis.2010.07.006
Eléments de statistiques à l'usage des étudiants en Médecine et en Biologie, 1998. ,
Drug-diagnostic co-development concept paper [en ligne], Disponible via, 2005. ,
Surrogate end points: how well do they represent patient-relevant end points?, Biomarkers in Medicine, vol.36, issue.3, pp.437-51, 2007. ,
DOI : 10.1016/0735-1097(94)90408-1
How can biomarkers become surrogate endpoints? EJC Supplements, pp.37-40, 2007. ,
DOI : 10.1016/j.ejcsup.2007.09.003
URL : https://doi.org/10.1016/j.ejcsup.2007.09.003
Complexities in drug trials: enrichment, biomarkers and surrogates, Biomarkers in Medicine, vol.2, issue.2, pp.109-121, 2008. ,
DOI : 10.1002/pds.1211
Imaging biomarkers as surrogate endpoints for drug development, European Journal of Nuclear Medicine and Molecular Imaging, vol.41, issue.S1, pp.6-10, 2006. ,
DOI : 10.1007/s00259-006-0129-z
Surrogate markers in clinical trials???Challenges and opportunities, Atherosclerosis, vol.206, issue.1, pp.8-16, 2009. ,
DOI : 10.1016/j.atherosclerosis.2008.12.009
Surrogate end points in clinical trials: are we being misled? Ann Intern Med, pp.605-618, 1996. ,
DOI : 10.7326/0003-4819-125-7-199610010-00011
Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials, Controlled Clinical Trials, vol.22, issue.5, pp.485-502, 2001. ,
DOI : 10.1016/S0197-2456(01)00153-2
Disponible via, Avandia European Public Assessment Report, 2004. ,
New clinical trials policy at FDA, Nature Biotechnology, vol.24, issue.9, p.1043, 2006. ,
DOI : 10.1038/nbt0906-1043
Adaptive Design in Confirmatory Trials, Mars 2010 Disponible via, 2010. ,
Adaptive Design Clinical Trials for Drugs and Biologics. Draft guidance [en ligne]. Février 2010 Disponible via : http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances, 2011. ,
Adaptive design clinical trials: Methodology, challenges and prospect, Indian Journal of Pharmacology, vol.42, issue.4, pp.201-208, 2010. ,
DOI : 10.4103/0253-7613.68417
URL : https://doi.org/10.4103/0253-7613.68417
Biomarker-adaptive clinical trial designs, Pharmacogenomics, vol.90, issue.12, pp.1679-82, 2010. ,
DOI : 10.1158/1078-0432.CCR-09-1357
Utility of Adaptive Strategy and Adaptive Design for Biomarker-facilitated Patient Selection in Pharmacogenomic or Pharmacogenetic Clinical Development Program, Journal of the Formosan Medical Association, vol.107, issue.12, pp.19-27, 2008. ,
DOI : 10.1016/S0929-6646(09)60005-X
Biomarker-Adaptive Threshold Design: A Procedure for Evaluating Treatment With Possible Biomarker-Defined Subset Effect, JNCI Journal of the National Cancer Institute, vol.69, issue.10, pp.1036-1079, 2007. ,
DOI : 10.1056/NEJMoa050736
Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design [en ligne]. Octobre, Disponible via, 2007. ,
I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy, Clinical Pharmacology & Therapeutics, vol.28, issue.1, pp.97-100, 2009. ,
DOI : 10.1038/clpt.2009.68
B-RAF is a therapeutic target in melanoma, Oncogene, vol.23, issue.37, pp.6292-6300, 2004. ,
DOI : 10.1038/sj.onc.1207785
BRAF, a target in melanoma, Cancer, vol.203, issue.June 1 suppl, pp.4902-4915, 2010. ,
DOI : 10.1016/S0002-9440(10)62327-9
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.9, pp.809-828, 2010. ,
DOI : 10.1056/NEJMoa1002011
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?, Drug Discovery Today, vol.15, issue.3-4, pp.3-4, 2010. ,
DOI : 10.1016/j.drudis.2009.11.006
Plexxikon Announces First Patient Dosed in Phase 3 Trial of PLX4032 (RG7204) for Metastatic Melanoma. Press release, Disponible sur, 2010. ,
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence, Lung Cancer, vol.71, issue.3, pp.249-57, 2011. ,
DOI : 10.1016/j.lungcan.2010.12.008
FDA alert for Healthcare Professionnals: Geftinib (marketed as Iressa) [en ligne] Disponible sur: http://www.fda.gov ,
Protein arrays and perspectives of medical applications, pp.5-6, 2007. ,
Biomarker technology roundup: from discovery to clinical applications, a broad set of tools is required to translate from the lab to the clinic, BioTechniques, vol.38, issue.S4, pp.30-32, 2005. ,
DOI : 10.2144/05384SU01
Effective Incorporation of Biomarkers into Phase II Trials, Clinical Cancer Research, vol.15, issue.6, pp.1898-905, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-2033
Tale of Two Drugs Hints at Promise for Genetic Testing [en ligne] New York Times Disponible via : http://www.nytimes.com, p.1, 2006. ,
Quality of Life and Prognosis in Heart Failure: Results of the Beta-Blocker Evaluation of Survival Trial (BEST), Journal of Cardiac Failure, vol.13, issue.9, pp.732-739, 2007. ,
DOI : 10.1016/j.cardfail.2007.07.001
Clinical biomarkers in drug discovery and development, Nature Reviews Drug Discovery, vol.75, issue.7, pp.566-80, 2003. ,
DOI : 10.1177/009127001773744260
Surrogate endpoints in clinical trials: Definition and operational criteria, Statistics in Medicine, vol.248, issue.4, pp.431-471, 1989. ,
DOI : 10.1002/sim.4780080407
The critical path initiative: Transforming the way FDA-regulated products are developed, evaluated, manufactured, and used Disponible sur: http://www.fda.gov/downloads, 2009. ,
Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus, Annals of Internal Medicine, vol.141, issue.6, pp.421-452, 2004. ,
DOI : 10.7326/0003-4819-141-6-200409210-00007
Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med, vol.358, pp.2545-59, 2008. ,
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website, British Journal of Cancer, vol.32, issue.2, pp.355-363, 2004. ,
DOI : 10.1093/nar/gkh073
BRAF and RAS mutations in human lung cancer and melanoma, Cancer Res, vol.62, pp.6997-7000, 2002. ,
Mutations of the BRAF Gene in Benign and Malignant Melanocytic Lesions, Journal of Investigative Dermatology, vol.121, issue.5, pp.1160-1162, 2003. ,
DOI : 10.1046/j.1523-1747.2003.12559.x